Cortalix, a Groningen-based biotech start-up has received an investment of 1 million euros from Future Tech Ventures, the Rabobank Innovation Loan, and various subsidies to accelerate the development and commercialization of its single-domain antibody technology. The...

Herman Steen, CEO of Cortalix, will present on "Single-Domain Antibody-Based Radiopharmaceuticals for Novel Cancer Stroma Targets" at the 24th Annual PepTalk Summit US, January 13-16, 2025 in San Diego, CA. For more information about Cortalix: www.cortalix.com Contact...

Herman Steen, CEO of Cortalix, will present a poster "A Synthetic Single-domain Antibody Discovery Platform for the Selection of Radiopharmaceuticals for Novel Fibrosis Targets" at the Festival of Biologics, October 15-17, 2024 in Basel, Switzerland. You are cordially...

Cortalix will join the existing consortium on a EUROSTARS grant of EUR 1.7 million for colorectal cancer molecular PET-imaging. EUROSTARS is a joint program of EUREKA and the European Commission, co-funded by the national budgets of 36 EUROSTARS Participating and...

Cortalix BV acquires patents and know-how from BiOrion on its single domain antibody platform and fibrogenesis biomarker radiopharmaceuticals. With these patents and know-how, Cortalix can continue to work on 2 active clinical programs around PET imaging of...